Clinical Trials Logo

EPP clinical trials

View clinical trials related to EPP.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04402489 Completed - XLP Clinical Trials

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

Start date: June 1, 2020
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, or stinging) associated with sunlight exposure in subjects with EPP or XLP aged 12-75.

NCT ID: NCT02979249 Completed - Clinical trials for Erythropoietic Protoporphyria

Oral Iron for Erythropoietic Protoporphyrias

EPP
Start date: December 2016
Phase: N/A
Study type: Interventional

In the medical literature there are conflicting reports on whether iron improves symptoms in patients with EPP and XLP. Giving iron to people who are iron deficient is thought to improve EPP symptoms. However, this has never been systematically tested. Therefore, the purpose of this study is to determine the effect of oral iron for EPP and XLP patients.

NCT ID: NCT01688895 Completed - Clinical trials for Erythropoietic Protoporphyria

Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact

Start date: July 2012
Phase:
Study type: Observational

The initial objective of this protocol is to assemble a well-documented group of patients with confirmed diagnoses of the erythropoietic protoporphyrias, including autosomal recessive Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP) for clinical, biochemical, and genetic studies. The long-term objectives are (1) to conduct a longitudinal investigation of the natural history, complications, and therapeutic outcomes in people with erythropoietic protoporphyria, (2) to systematically investigate the psychological effects of the erythropoietic protoporphyrias on children and adults, and (3) to investigate the correlation between the identified genotypes and the resulting clinical presentation, also determining the possible interaction of other genetic markers.